Troncone L, Rufini V, Maussier M L, Valenza V, Daidone M S, Luzi S, De Santis M
Department of Nuclear Medicine, Università Cattolica del Sacro Cuore, Rome, Italy.
J Nucl Biol Med (1991). 1991 Oct-Dec;35(4):327-31.
Therapeutic doses of [131I]metaiodobenzylguanidine (131I-MIBG) were administered to 5 patients, 3 men and 2 women aged from 33 to 66 years, with proven medullary thyroid carcinoma (one "intermediate" papillary/medullary tumor). The treatment procedure consisted of single doses (3.7-8.5 GBq) of 131I-MIBG given by slow i.v. infusion at 2-8 month intervals. In two advanced-stage patients the treatment played an important palliative role, ranging from an objective response (substantial, but not complete, regression of the tumor) to pain relief which was significant for these patients. In three other cases with residual/recurrent tumor, 131I-MIBG complemented conventional treatment in the attempt to effect a cure which actually was achieved in one case. The only side-effect observed was a transient, mild hematologic toxicity in some cases.
对5例患者（3名男性和2名女性，年龄33至66岁）给予治疗剂量的[131I]间碘苄胍（131I - MIBG），这些患者均确诊为甲状腺髓样癌（1例为“中间型”乳头状/髓样肿瘤）。治疗过程包括以2至8个月的间隔通过静脉缓慢输注给予单剂量（3.7 - 8.5 GBq）的131I - MIBG。在2例晚期患者中，治疗起到了重要的姑息作用，从客观缓解（肿瘤显著但未完全消退）到疼痛缓解，对这些患者意义重大。在另外3例有残留/复发性肿瘤的病例中，131I - MIBG辅助传统治疗以试图实现治愈，其中1例实际实现了治愈。观察到的唯一副作用是部分病例出现短暂、轻微的血液学毒性。
